GSA Capital Partners LLP purchased a new position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL – Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 374,260 shares of the company’s stock, valued at approximately $1,815,000.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Sivia Capital Partners LLC purchased a new stake in Zentalis Pharmaceuticals in the 4th quarter valued at about $27,000. CTC Alternative Strategies Ltd. purchased a new position in shares of Zentalis Pharmaceuticals during the first quarter worth approximately $29,000. Qube Research & Technologies Ltd bought a new stake in shares of Zentalis Pharmaceuticals during the second quarter valued at approximately $37,000. Voleon Capital Management LP bought a new stake in shares of Zentalis Pharmaceuticals during the third quarter valued at approximately $41,000. Finally, State of Wyoming purchased a new stake in shares of Zentalis Pharmaceuticals in the first quarter valued at approximately $67,000.
Analysts Set New Price Targets
ZNTL has been the topic of several research reports. Wall Street Zen downgraded Zentalis Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Saturday, August 8th. Mizuho began coverage on Zentalis Pharmaceuticals in a report on Friday, July 17th. They issued an “outperform” rating and a $8.00 target price for the company. HC Wainwright reissued a “buy” rating and set a $10.00 price target on shares of Zentalis Pharmaceuticals in a research report on Friday, May 22nd. Weiss Ratings restated a “sell (d-)” rating on shares of Zentalis Pharmaceuticals in a research note on Monday, July 6th. Finally, Rodman & Renshaw assumed coverage on Zentalis Pharmaceuticals in a report on Thursday, July 23rd. They issued a “buy” rating and a $11.00 price objective for the company. Four equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $6.75.
Zentalis Pharmaceuticals Price Performance
Shares of NASDAQ:ZNTL opened at $3.56 on Monday. The company has a market capitalization of $255.15 million, a price-to-earnings ratio of -1.83 and a beta of 1.92. Zentalis Pharmaceuticals, Inc. has a 52 week low of $1.21 and a 52 week high of $6.95. The firm has a 50 day moving average of $4.34 and a 200 day moving average of $3.64.
Zentalis Pharmaceuticals (NASDAQ:ZNTL – Get Free Report) last posted its earnings results on Thursday, August 6th. The company reported ($0.59) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.10). On average, sell-side analysts expect that Zentalis Pharmaceuticals, Inc. will post -2.14 EPS for the current year.
About Zentalis Pharmaceuticals
Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.
The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.
Featured Stories
- Five stocks we like better than Zentalis Pharmaceuticals
- The Metals Company’s Big Bet Now Comes Down to a License
- OneSpaWorld Keeps Turning Cruise Demand Into Record Earnings
- Meta and Tesla Are Rebounding From Oversold Levels—Now What?
- AMG’s Alternatives Boom Powers Record Growth
Want to see what other hedge funds are holding ZNTL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL – Free Report).
Receive News & Ratings for Zentalis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zentalis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
